🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: faldaprevir

Found 50 matching trials

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

PHASE2

The objective was to investigate the antiviral effect, safety, and pharmaco...

Status

Completed

Location

1220.5.0001 Boehringer Ingelheim Investigational Site

Start Date

2008-10

Trial ID

NCT00774397

Treatments Being Tested

BI 201335 NA 240 mg QD / LI PegIFN/RBV BI 201335 NA 120mg QD / LI PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg BID PegIFN/RBV PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV Placebo

Drug Drug Interaction of BI 201335 and Tenofovir

PHASE1

The objective of this study is to evaluate the drug-drug interaction potent...

Status

Completed

Location

1220.50.0001 Boehringer Ingelheim Investigational Site

Start Date

2011-04

Trial ID

NCT01340196

Treatments Being Tested

tenofovir/BI 201335

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

PHASE1

Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (F...

Status

Terminated

Location

1241.31.2 Boehringer Ingelheim Investigational Site

Start Date

2013-11

Trial ID

NCT01941615

Treatments Being Tested

faldaprevir Microgynon®BI 207127

Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers

PHASE1

Obtain interaction data between BI 201335 and Efavirenz to guide dosing for...

Status

Completed

Location

1220.20.41001 Boehringer Ingelheim Investigational Site

Start Date

2011-06

Trial ID

NCT01371006

Treatments Being Tested

low dose normal dose low dose

Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

PHASE1

The objective of the current study is to investigate the relative bioavaila...

Status

Completed

Location

1220.46.1 Boehringer Ingelheim Investigational Site

Start Date

2013-01

Trial ID

NCT01764945

Treatments Being Tested

BI 201335 (Reference)BI 201335 (Test)BI 201335 (Test)BI 201335 (Test)BI 201335 (Reference)BI 201335 (Test)BI 201335 (Test)BI 201335 (Test)

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

PHASE1

The objective of this trial was to investigate safety, tolerability, and ph...

Status

Completed

Location

Multiple Locations

Start Date

2008-04

Trial ID

NCT02182297

Treatments Being Tested

BI 201335 NA in single rising doses Placebo

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

PHASE2

The objective of this trial is to investigate tolerability, safety, pharmac...

Status

Completed

Location

1241.25.002 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01528735

Treatments Being Tested

BI 207127 NA peginterferon Ribavirin Ribavirin BI 207127 NA BI 201335 NA BI 201335 NA peginterferon

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

PHASE1

The main objective of this study is to investigate the influence of mild, m...

Status

Completed

Location

1220.58.1 Boehringer Ingelheim Investigational Site

Start Date

2012-04

Trial ID

NCT01580306

Treatments Being Tested

BI 201335 BI 201335

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

PHASE2

The current Standard of Care (SOC) for chronic HCV infection, which is pegy...

Status

Completed

Location

1220.14.003 Boehringer Ingelheim Investigational Site

Start Date

2009-07

Trial ID

NCT00947349

Treatments Being Tested

ribavirin (RBV)pegylated interferon (PegIFN) alfa-2a pegylated interferon (PegIFN) alfa-2a ribavirin (RBV)BI 201335 NA low placebo pegylated interferon (PegIFN) alfa-2a ribavirin (RBV)BI 201335 NA high BI 201335 NA low BI 201335 NA high placebo BI 201335 NA high Placebo

Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir

PHASE1

The primary objective of this trial is to investigate the effect of food an...

Status

Completed

Location

1220.59.1 Boehringer Ingelheim Investigational Site

Start Date

2012-09

Trial ID

NCT01694706

Treatments Being Tested

faldaprevir faldaprevir omeprazole faldaprevir

Previous Next